DK0622458T3 - Adrenomedullin - Google Patents

Adrenomedullin

Info

Publication number: DK0622458T3
Authority: DK; Denmark
Prior art keywords: proam; proadrenomedullin; peptide; adrenomedullin; peptides
Prior art date: 1993-04-26

Application number

DK94302948T

Other languages

English (en)

Inventor

Kenji Kangawa

Kazuo Kitamura

Hisayuki Matsuo

Tanenao Eto

Original Assignee

Kenji Kangawa

Shionogi & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-04-26

Filing date

1994-04-25

Publication date

2003-05-19

1994-04-25 Application filed by Kenji Kangawa, Shionogi & Co filed Critical Kenji Kangawa

2003-05-19 Application granted granted Critical

2003-05-19 Publication of DK0622458T3 publication Critical patent/DK0622458T3/da

Links

102000004379 Adrenomedullin Human genes 0.000 title abstract 7
101800004616 Adrenomedullin Proteins 0.000 title abstract 7
ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 title abstract 3
108090000765 processed proteins & peptides Proteins 0.000 abstract 4
230000002401 inhibitory effect Effects 0.000 abstract 2
102000034567 proadrenomedullin Human genes 0.000 abstract 2
108010012004 proadrenomedullin Proteins 0.000 abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
150000001413 amino acids Chemical group 0.000 abstract 1
150000003943 catecholamines Chemical class 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
230000001077 hypotensive effect Effects 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
230000028327 secretion Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/003—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by transforming the C-terminal amino acid to amides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Analytical Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Toxicology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Fats And Perfumes (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Saccharide Compounds (AREA)

DK94302948T 1993-04-26 1994-04-25 Adrenomedullin DK0622458T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP9985693		1993-04-26
JP18310793		1993-07-23
JP29873693		1993-11-29
JP6079035A JP2774769B2 (ja)	1993-04-26	1994-04-18	アドレノメデュリン

Publications (1)

Publication Number	Publication Date
DK0622458T3 true DK0622458T3 (da)	2003-05-19

Family

ID=27466245

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK94302948T DK0622458T3 (da)	1993-04-26	1994-04-25	Adrenomedullin

Country Status (9)

Country	Link
US (4)	US5639855A (da)
EP (1)	EP0622458B1 (da)
JP (1)	JP2774769B2 (da)
KR (1)	KR100312443B1 (da)
AT (1)	ATE231553T1 (da)
CA (1)	CA2122112C (da)
DE (1)	DE69432033T2 (da)
DK (1)	DK0622458T3 (da)
ES (1)	ES2191674T3 (da)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997007214A1 (en) *	1995-08-18	1997-02-27	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology
US5888963A (en) *	1996-04-18	1999-03-30	Auckland Uniservices Limited	Treatment of bone disorders with adrenomedullin
US6440421B1 (en) *	1996-04-18	2002-08-27	Auchkland Uniservices Limited	Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
WO1999016406A2 (en)	1997-09-26	1999-04-08	Auckland Uniservices Limited	Therapeutic method
JP4610142B2 (ja) *	1999-06-23	2011-01-12	寒川賢治	膀胱平滑筋の受動的伸展を促進するための組成物
US7326680B1 (en)	1999-06-23	2008-02-05	Shionogi & Co., Ltd.	Uterine contraction inhibitors
FR2821080B1 (fr) *	2001-02-20	2003-12-19	Sanofi Synthelabo	Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
JPWO2003078460A1 (ja) *	2002-03-19	2005-07-14	株式会社オンコレックス	ペプチド、該ペプチドを含有する医薬組成物及び癌治療用医薬組成物
US20040121375A1 (en) *	2002-09-30	2004-06-24	Bayer Pharmaceuticals Corporation	Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US7364719B2 (en) *	2002-10-04	2008-04-29	The United States Of America As Represented By The Department Of Health And Human Services	Vasoregulating compounds and methods of their use
EP1575511A4 (en) *	2002-11-07	2006-06-28	Us Gov Health & Human Serv	NEW TARGET FOR ANGIOGENESIS AND ANTI-ANGIOGENESIS THERAPY
US6727277B1 (en)	2002-11-12	2004-04-27	Kansas State University Research Foundation	Compounds affecting cholesterol absorption
DE10316583A1 (de) *	2003-04-10	2004-10-28	B.R.A.H.M.S Aktiengesellschaft	Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
AU2004273057C1 (en) *	2003-09-08	2011-06-30	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide
WO2005103720A1 (en) *	2004-03-29	2005-11-03	Medstar Research Institute, Inc.	Methods of diagnosing cardiovascular disease
US8703693B2 (en) *	2004-03-31	2014-04-22	The Feinstein Institute For Medical Research	Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
EP1742651B1 (en) *	2004-03-31	2011-03-09	The Feinstein Institute for Medical Research	Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
EP1844158A4 (en) *	2004-12-06	2010-09-08	Univ Johns Hopkins	BIOMARKER FOR INFLAMMATORY ENDURANCE
DE102005003687A1 (de)	2005-01-26	2006-07-27	Sphingo Tec Gmbh	Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
EP1878436B1 (en) *	2005-03-07	2014-07-23	National Cerebral and Cardiovascular Center	Method for regenerating and repairing damaged tissues using adrenomedullin
JP4505640B2 (ja) *	2005-04-12	2010-07-21	国立大学法人宮崎大学	心筋障害の予防又は治療剤
WO2006112390A1 (ja) *	2005-04-14	2006-10-26	Japan As Represented By General Director Of Agency Of National Cardiovascular Center	脂肪由来前駆細胞およびその利用
DE102005036094A1 (de) *	2005-08-01	2007-02-08	B.R.A.H.M.S Ag	In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen
US8906857B2 (en) *	2005-12-01	2014-12-09	B.R.A.H.M.S. Gmbh	Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
JP4976412B2 (ja)	2005-12-01	2012-07-18	ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー	エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法
DE102006060112A1 (de)	2006-12-20	2008-06-26	Brahms Aktiengesellschaft	Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
US9193756B2 (en)	2008-02-19	2015-11-24	National University Corporation Asahikawa Medical College	Adrenomedullin production enhancer
JP5954736B2 (ja) *	2011-01-12	2016-07-20	国立大学法人宮崎大学	難治性炎症性腸疾患の予防又は治療方法
ES2387240B2 (es) *	2011-01-31	2013-04-26	Fundación Rioja Salud	Péptido capaz de aumentar la velocidad de desplazamiento de una kinesina o su homóloga funcional sobre microtúbulos.
US11067586B2 (en)	2011-11-16	2021-07-20	Sphingotec Gmbh	Adrenomedullin assays and methods for determining mature adrenomedullin
IL283215B2 (en) *	2011-11-16	2024-05-01	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment and pharmaceutical compostions comprising the same
EP2780717B1 (en)	2011-11-16	2016-12-21	sphingotec GmbH	Adrenomedullin assays and methods for determining mature adrenomedullin
ES2494190T3 (es) *	2011-11-16	2014-09-15	Adrenomed Ag	Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo
SG11201402358RA (en) *	2011-11-16	2014-06-27	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
PT3553084T (pt)	2011-11-16	2023-02-17	Adrenomed Ag	Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou esqueleto não-ig anti-adm para prevenção ou redução de disfunção de órgãos ou insuficiência de órgãos num paciente possuindo uma doença crónica ou aguda ou condição aguda
SG11201402354YA (en)	2011-11-16	2014-06-27	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
CN108362885B (zh)	2013-03-20	2021-05-14	斯弗因高泰克有限公司	用于指导血压下降疗法的肾上腺髓质素
CN106164088B (zh)	2014-03-20	2021-11-23	国立大学法人宫崎大学	长效肾上腺髓质素衍生物
AP2017009826A0 (en) *	2014-09-26	2017-03-31	Bayer Pharma AG	Stabilized adrenomedullin derivatives and use thereof
NZ740534A (en)	2015-09-18	2019-07-26	Univ Miyazaki	Long-acting adrenomedullin derivative
CN109716136B (zh)	2016-07-08	2023-09-22	斯弗因高泰克有限公司	肾上腺髓质素用于评估急性心力衰竭患者的充血
JP7727371B2 (ja)	2016-12-16	2025-08-21	アドレノメトアクチェンゲゼルシャフト	うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場
EP3339324A1 (en)	2016-12-22	2018-06-27	sphingotec GmbH	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
EP3604538A4 (en) *	2017-03-29	2020-12-30	University of Miyazaki	LONG-ACTING ADRENOMEDULLINE DERIVATIVE
EP3438668A1 (en)	2017-08-04	2019-02-06	B.R.A.H.M.S GmbH	Diagnosis and risk stratification of fungal infections
MX2020004072A (es)	2017-10-18	2020-07-28	Adrenomed Ag	Monitoreo de terapia bajo tratamiento con un aglutinante anti-adrenomodulina (adm).
EP3502706A1 (en)	2017-12-20	2019-06-26	B.R.A.H.M.S GmbH	Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin
JP2021513077A (ja)	2018-02-08	2021-05-20	シュピーンゴテックゲゼルシャフトミットベシュレンクテルハフツング	認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー
EP3715851A1 (en)	2019-03-29	2020-09-30	B.R.A.H.M.S GmbH	Prescription of remote patient management based on biomarkers
JP7575400B2 (ja)	2019-03-29	2024-10-29	ベー．エル．アー．ハー．エム．エスゲゼルシャフトミットベシュレンクテルハフツング	バイオマーカーに基づく遠隔患者管理の処方
EP3871689A1 (en)	2020-02-26	2021-09-01	sphingotec GmbH	Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
US20230104578A1 (en)	2020-02-27	2023-04-06	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
BR112022015215A2 (pt)	2020-02-27	2022-10-11	4TEEN4 Pharmaceuticals GmbH	Dpp3 para orientação, monitoramento e estratificação de terapia de anticorpos nt-adm em pacientes com choque
JP2023518380A (ja)	2020-03-16	2023-05-01	アドレノメトアクチェンゲゼルシャフト	コロナウイルスに感染した患者におけるプロアドレノメデュリンまたはそのフラグメント、およびアドレノメデュリンに対する結合剤による治療
WO2021201271A1 (ja)	2020-04-02	2021-10-07	国立大学法人宮崎大学	新規アドレノメデュリン類縁体、その製造方法及びその医薬用途
EP4023218A1 (en)	2020-12-02	2022-07-06	S-Form Pharma	Combination therapy for patients having acute and/or persistent dyspnea
WO2022234111A1 (en)	2021-05-07	2022-11-10	Sphingotec Gmbh	Mature adrenomedullin for therapy stratification of corticosteroids in critically ill patients
IL318667A (en)	2022-07-29	2025-03-01	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
AU2023315168A1 (en)	2022-07-29	2025-02-13	4TEEN4 Pharmaceuticals GmbH	Prediction of an increase of dpp3 in a patient with septic shock
WO2026046982A1 (en)	2024-08-26	2026-03-05	Pam Theragnostics Gmbh	A method for the prediction of a risk or severity of side effects in a cancer patient that is to be treated or has been treated with immune effector cell therapy (iect)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4708934A (en) *	1984-09-27	1987-11-24	Unigene Laboratories, Inc.	α-amidation enzyme
JPH04282399A (ja) *	1991-03-08	1992-10-07	Fujisawa Pharmaceut Co Ltd	放射性ヨウ素標識インシュリン様成長因子ｉ
HU224350B1 (hu) *	1993-08-09	2005-08-29	Société de Conseils de Recherches et d'ApplicationScientifiques, S.A.S. Á	Gyógyhatású peptidszármazékok

1994
- 1994-04-18 JP JP6079035A patent/JP2774769B2/ja not_active Expired - Lifetime
- 1994-04-25 ES ES94302948T patent/ES2191674T3/es not_active Expired - Lifetime
- 1994-04-25 CA CA002122112A patent/CA2122112C/en not_active Expired - Lifetime
- 1994-04-25 DE DE69432033T patent/DE69432033T2/de not_active Expired - Lifetime
- 1994-04-25 DK DK94302948T patent/DK0622458T3/da active
- 1994-04-25 EP EP94302948A patent/EP0622458B1/en not_active Expired - Lifetime
- 1994-04-25 AT AT94302948T patent/ATE231553T1/de active
- 1994-04-26 US US08/233,389 patent/US5639855A/en not_active Expired - Lifetime
- 1994-04-26 KR KR1019940008834A patent/KR100312443B1/ko not_active Expired - Fee Related
1995
- 1995-06-07 US US08/486,596 patent/US5837823A/en not_active Expired - Lifetime
1997
- 1997-02-18 US US08/801,863 patent/US5830703A/en not_active Expired - Lifetime
1998
- 1998-01-07 US US09/004,713 patent/US5910416A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU6064894A (en)	1994-10-27
ES2191674T3 (es)	2003-09-16
US5910416A (en)	1999-06-08
US5639855A (en)	1997-06-17
EP0622458A3 (en)	1996-06-12
ATE231553T1 (de)	2003-02-15
EP0622458A2 (en)	1994-11-02
US5837823A (en)	1998-11-17
KR100312443B1 (ko)	2002-02-28
AU678212B2 (en)	1997-05-22
JP2774769B2 (ja)	1998-07-09
JPH07196693A (ja)	1995-08-01
EP0622458B1 (en)	2003-01-22
DE69432033T2 (de)	2003-09-25
US5830703A (en)	1998-11-03
CA2122112C (en)	1999-02-16
DE69432033D1 (de)	2003-02-27
CA2122112A1 (en)	1994-10-27

Publication	Publication Date	Title
ATE231553T1 (de)	2003-02-15	Adrenomedullin
BR9500732A (pt)	1995-10-24	Peptídio imunologicamente ativo,fragmento de DNA isolado,kit de teste e aplicação
DK150992A (da)	1992-12-17	Fremgangsmaade til fremstilling af et polypeptidfragment af faktor viii:c, dna-sekvens og ekstrachromosomalt element indeholdende en saadan dna-sekvens, som koder herfor
ATE105867T1 (de)	1994-06-15	Immunaffinitäts-reinigungssystem.
DK532284A (da)	1984-11-08	Fremgangsmaade til bestemmelse af antigenaktive aminosyresekvenser
IE841734L (en)	1985-01-07	Modified protease inhibitors
ES2129487T3 (es)	1999-06-16	Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
IL97566A0 (en)	1992-06-21	Antigenic proteins,their production and their use in the prevention of coccidiosis
ZA8860B (en)	1988-10-26	Pancreatic secretory trypsin inhibitor and variants thereof produced by a recombinant host,process,expression vector and recombinant host therefor and pharmaceutical use thereof
DK1336109T3 (da)	2007-10-15	Kit og fremgangsmåde til at påvise proteinet EMS-1
DK611386A (da)	1987-02-18	Recombinant humant fsh, fremgangsmaade til fremstilling deraf og vektorer og celler til anvendelse ved fremgangsmaaden
DE69331501D1 (de)	2002-03-14	Unterdrückung der Proliferation von T-Zellen mittels Peptidfragmenten des basischen Proteins aus Myelin
KR900700500A (ko)	1990-08-13	재조합 유전자 기술에 의한 에라스타제 억제 폴리펩티드 제조방법 및 에라스타제 억제 폴리펩티드
MX167236B (es)	1993-03-11	Peptidos sinteticos de timosina -1 y metodo para su obtencion
GB9816514D0 (en)	1998-09-30	Novel method
EP0152612A3 (en)	1986-04-16	Determination of fibrin with fibrin-specific antibodies
ATE190318T1 (de)	2000-03-15	Pcna bindende substanz
CY1111763T1 (el)	2015-10-07	ΑΝΤΙΣΩΜΑΤΑ ΕΝΑΝΤΙΟΝ ΤΗΣ ΠΡΩΤΕΪΝΗΣ p51
AUPP627498A0 (en)	1998-10-22	Novel peptides - i
DK450187D0 (da)	1987-08-28	Fremgangsmaade til fremstilling af proteiner
ES2158235T3 (es)	2001-09-01	Peptidos antigenicos con substituciones de glicina.
ES2051152B1 (es)	1994-12-16	Procedimiento de sistesis de peptidos con capacidad de detectar anticuerpos anti-virus de la hepatitis c (vhc) en suero de individuos afectados.
AR033043A1 (es)	2003-12-03	Proteina del tipo reg
DK369888A (da)	1988-07-04	Peptidforbindelser